Metformin improves endothelial function, endothelial progenitor cells and cardiovascular risk factors in type 1 diabetes

Not Applicable

Completed

• Conditions: Type 1 diabetes and cardiovascular disease; Nutritional, Metabolic, Endocrine; Insulin-dependent diabetes mellitus

• Registration Number: ISRCTN26092132
• Lead Sponsor: Gateshead Health NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07-13
• Last Update Posted: 27 February 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Type 1 diabetes mellitus
2. Aged 16 years or over
3. HbA1c <= 8.5
4. Duration of diabetes of at least 5 years
5. Stable diabetes control for at least 2 months

Exclusion Criteria

1. Glomerular filtration rate (GFR) < 45 ml/ min/ 1.73m2
2. Woman of childbearing age planning pregnancy
3. Pregnancy and/or lactation
4. Proliferative diabetic retinopathy
5. Cardiovascular disease/ischemic heart disease (IHD)
6. Peripheral vascular disease
7. Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
8. Suspected hypoglycaemia unawareness
9. Impaired cognitive function/ unable to give informed consent
10. History of lactic acidosis
11. Contraindications to metformin
12. History of alcohol problem or drug abuse

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. EPCs<br>2. Hill Colony Assay <br>3. Endothelial function <br><br>Measured before and after metformin therapy

Secondary Outcome Measures

Name	Time	Method
o secondary outcome measures